Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
about
Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approachThe genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and managementPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisQuinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II moleculesCoculture of Primary Motor Neurons and Schwann Cells as a Model for In Vitro Myelination.Copy number variation in human health, disease, and evolution.Determinants of reduced health-related quality of life in pediatric inherited neuropathies.The PMP22 gene and its related diseases.Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.Peripheral myelin protein-22 (PMP22) modulates alpha 6 integrin expression in the human endometriumSchwann cell mitochondrial metabolism supports long-term axonal survival and peripheral nerve functionFoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies.Colony-stimulating factor-1 mediates macrophage-related neural damage in a model for Charcot-Marie-Tooth disease type 1XProgesterone synthesis in the nervous system: implications for myelination and myelin repair.Role of neuroactive steroids in the peripheral nervous systemInherited peripheral neuropathies.Update on Charcot-Marie-Tooth disease.Molecular mechanisms of inherited demyelinating neuropathies.Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling.Experimental therapeutics in hereditary neuropathies: the past, the present, and the future.Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model.PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.Review of the GAS3 Family of Proteins and their Relevance to Cancer.Signals to promote myelin formation and repair.Molecular diagnostics: between chips and customized medicine.Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease.Neural and molecular features on Charcot-Marie-Tooth disease plasticity and therapy.Animal models and therapeutic prospects for Charcot-Marie-Tooth disease.Charcot-Marie-Tooth disease and pathways to molecular based therapies.Therapeutic options in Charcot-Marie-Tooth diseases.A Review of X-linked Charcot-Marie-Tooth Disease.Application of differentiated human tonsil-derived stem cells to trembler-J mice.Promoting peripheral myelin repair.MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice.PMP22 expression in dermal nerve myelin from patients with CMT1A.Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II.The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A.PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.
P2860
Q26768401-830527B8-F06E-413F-AE0E-9F4702C3CCF7Q26777319-80D4CEBD-42C0-4D30-956D-699564688A4AQ27320796-813224AE-332D-4DC2-89FB-F8B98DB97CEDQ28478607-12ACAE99-029B-4D46-B92E-679DB663479FQ30667587-7E366ED7-F5E2-4E09-B229-5C0C8051D3A0Q34019142-AD8A502C-8657-4BB8-87D1-0C68B492C0A3Q34098654-F7541CCC-EA75-43CF-AE43-DA8411418F7DQ34316615-4C1BC3AF-8EC5-40BE-998D-097879B02E64Q34788066-31F2CD90-B263-49DF-AA6D-A289311130E7Q35032503-7065E5B2-DA76-4DC4-A736-2CC8BB99FB11Q35138509-5B5427A5-9B94-4525-A2E8-C4710324DBF4Q35305030-C0118C59-F470-47A3-94C2-F7C5E972D3E6Q35706394-7196C561-A744-43B6-9D97-3E5F8274D859Q35743169-7EE5793E-3A27-428D-97A6-47DD5A1A7A42Q35972151-AAE73154-C5B4-4C34-A148-03922FE7CE3DQ36822088-0D9D0D8C-966B-40DC-B43C-78314233B5F9Q36937164-8D574682-46A2-4F8F-98E2-B518DE88558AQ36942808-AD84FC20-4316-4FBF-B6E8-1600918B7993Q36991308-579BD62F-D0A9-43E8-93E5-6843F97422BAQ37329508-1FD65202-FFE5-4CDC-953B-1C8AAF2C4618Q37693215-14E050FC-8EEE-46F8-A7BA-6CFC09F2633FQ37715520-ABD3858A-4A84-4A00-8F38-FBE4D3305D77Q37716267-73B79524-76CC-402A-93B7-83CEB1096E25Q37734207-CF4B321A-C842-4272-A7EF-90D087DD1124Q37742118-66C828B0-D924-4246-BB3F-83C8F18F5A61Q38007033-A839AEDE-45B3-4B7B-9699-10DB78BBB7A1Q38022624-AB71479E-CAAA-41A0-9408-E000B33C878CQ38126454-F212296D-025E-41AE-A6DE-A9EEE1DA0EE6Q38201741-3185ECA2-AE6F-47F9-8DE4-AD10D557D850Q38363677-14254266-4699-45B2-9752-817665EA11DFQ38589445-A9262EED-6ACC-4645-9355-F5FF7A70CC84Q38695246-17C331A1-2084-4CAE-95FC-38BDACF502A5Q38808666-15798B5B-E0FB-49CB-801D-69D78B888069Q39403441-87EF6FD1-2239-43AF-B825-EC7F96A3A68BQ39673261-89BAD4F9-5D37-4CA5-A06C-609F6D82E0FCQ40617443-31DD56FF-AFE4-4248-8E0A-FEC7539FB849Q41908068-520E3722-F9A2-48AA-9365-E3C87D201CD0Q42286251-90E2EAC9-3850-48B2-9D96-0637A1282F8CQ42443417-0FD25313-3356-493B-B3DA-5156DE757234Q45875397-719D86F3-4FED-4122-8AFC-B397D588390B
P2860
Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antiprogesterone therapy uncou ...... rat model of CMT1A neuropathy.
@en
type
label
Antiprogesterone therapy uncou ...... rat model of CMT1A neuropathy.
@en
prefLabel
Antiprogesterone therapy uncou ...... rat model of CMT1A neuropathy.
@en
P2093
P356
P1433
P1476
Antiprogesterone therapy uncou ...... rat model of CMT1A neuropathy.
@en
P2093
David Liebetanz
Michael W Sereda
Thomas Prukop
Wiebke Mobius
P356
10.1002/ANA.21026
P577
2007-01-01T00:00:00Z